Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase[...]
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
05/10/2024 | Press release | Distributed by Public on 05/10/2024 12:34
Please select the service you want to use:
Smartlinks | Fidelity Private Credit Trust | Company News | Investment Funds | Private Companies | Investment Trusts
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact